
In the News
Sunflower Therapeutics Announces the First System Delivery and Installation of the Daisy Petal™ Perfusion Bioreactor System to BioBuilder
The system is installed in the newly commissioned BioBuilder Learning Lab space in Allston Labworks for use in training local students, educators, and incumbent workers to be a passionate part of the growing biotechnology workforce.
Sunflower Therapeutics Announces an Exclusive Sales Representation Agreement with Optimal Biotech Group
Customers in California, Oregon, Washington, Idaho, Montana, and British Columbia can now purchase the Daisy Petal™
Sunflower Therapeutics Engages PharmNXT Biotech LLP as Distributor for the Daisy Petal™ Perfusion Bioreactor System
Daisy Petal™ is now commercially launched and available for sale in India, Singapore, Thailand, Indonesia, Malaysia, and South Korea
Women in Science: ‘Stay curious, be persistent, and embrace the power of mentorship’, says Kerry Love of Sunflower Therapeutics
Kerry Love co-founded Sunflower Therapeutics, where she now serves as CEO and president. She shares her journey with BioPharmaReporter.
Women in Science: Laura Crowell on overcoming imposter syndrome
As Director of R&D at Sunflower Therapeutics, Laura Crowell works with a team developing biologic medicines and vaccines. She sits down with BioPharma-Reporter to share her journey.
Sunflower Therapeutics Closes $3M Simple Agreement for Future Equity (SAFE) with Oversubscription
Sunflower Therapeutics (Sunflower), a public benefit corporation transforming global access to protein manufacturing capacity for diverse applications, announced today the oversubscription of a $3M Simple Agreement for Future Equity (SAFE), which underscores ongoing support for the company’s commercial goals.
Sunflower Therapeutics’ Daisy Petal™ Named “Lifescience Manufacturing Solution of the Year” by BioTech Breakthrough
Recognizing Innovation in Global Life Sciences and Biotechnology HINGHAM, MA, NOVEMBER 19, 2024 ‒ At Sunflower Therapeutics, we’re on a mission to make protein production more accessible, efficient, and cost-effective, and it’s exciting to see our efforts recognized!...
Sunflower Therapeutics Announces SK bioscience’s $2M SAFE Investment
Sunflower Therapeutics, a public benefit corporation transforming global access to protein manufacturing capacity for diverse applications, today announced that SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, has participated in Sunflower’s simple agreement for future equity (SAFE), a flexible agreement providing future equity rights without immediate valuation, with a $2M subscription to solidify their support for the companies’ ongoing research and development R&D collaborations.
Sunflower Therapeutics Awarded $9+M
Grants from the Bill & Melinda Gates Foundation support the optimization of the Dahlia™ small-footprint protein manufacturing system and the de-risking of several protein candidates using Sunflower’s proprietary manufacturing approach.
Sunflower Therapeutics Delivers First Daisy Petal™ System as Part of Early Access Program
Sunflower Therapeutics, a public benefit corporation focused on transforming access to biologics medicines for patients worldwide, has delivered its first system for biomanufacturing, the Daisy Petal™ fermentation system.